<h3>Background</h3> Evidence on the management of pregnant patients with lupus activity is limited. The choice of pharmacological treatment is decisive for an adequate outcome. <h3>Objectives</h3> To show the experience of management with intravenous immunoglobulin (IVIG) in pregnant patients with severe active lupus. <h3>Methods</h3> Case series from January 2020 to November 2022 of pregnant patients being managed with IVIG in a hospital in Bogotá, Colombia. <h3>Results</h3> Out a total of 33 pregnant patients evaluated during the period, three cases of the use of IVIG in pregnant patients with severe lupus were found (Figure 1). The main involvement of lupus was renal (increased proteinuria), hematological (thrombocytopenia) and vascular [Intrauterine growth restriction (IUGR) and threatened abortion]. Average age was 30.3 years. One of the patients was diagnosed de novo with the disease during pregnancy, IVIG was given due to thrombocytopenia with resolution, but she presented fetal loss due to sepsis, in addition she had maternal vascular complications due to polyautoimmunity with antiphospholipid syndrome. The other two patients underwent IVIG at 24 weeks, one of them reached week 30 without considering new immunoglobulin applications, in the second case due to persistent proteinuria she received two additional cycles reaching 33 weeks of gestation. In both cases, a cesarean section was performed by IUGR at 30 and 33 weeks respectively. There were no complications associated with the newborns, with good response to proteinuria and resolution of cytopenias (See Table 1). There were no adverse drug events reported in any case. <h3>Conclusion</h3> IVIG can be a useful medication for the treatment of severe active lupus in pregnant patients, mainly in those with renal and hematological involvement. It is important to highlight IVIG has high safety and few side effects, on the mothers with lupus and their offspring's. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.